1. HBW Insight
  2. >>Health
  3. >>Business

Dexcom’s Stelo Continuous Glucose Monitor Now Available OTC In US

 
• By Natasha Barrow

Dexcom announced the launch of Stelo, the first non-prescription continuous glucose monitoring system to hit the US market, but is likely going to face competition soon from Abbott.

• Source: Shutterstock

DexCom, Inc.’s Stelo continuous glucose monitor (CGM) became available in the US on 26 August for diabetics, prediabetics and healthy consumers alike, making it the first such product sold in the country that does not require a prescription.

While first to market, Dexcom is likely to face competition soon from its closest rival, Abbott , which is planning to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Beauty

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.

Coty’s Next Phase Of ‘All-In To Win’ Strategy Should Generate $130M Savings

 
• By Eileen Francis

Coty’s ‘All-in to Win’ program enters the next phase, which sets aggressive savings over the next two years in part by simplifying and scaling its operating model, in addition to boosting its innovation impact.

P&G: Innovation, Pricing ‘Short-Term Levers’ For Tariffs Adding Up To $1.5Bn In Costs Annually

 
• By Eileen Francis

The Procter & Gamble Company is working to mitigate the impact of tariffs, which will add up to $1.5bn in costs annually. The firm has lowered its fiscal 2025 outlook.